Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non‐small cell lung cancer undergoing stereotactic body radiotherapy
The Clinical Respiratory Journal · 2024
DOI: 10.1111/crj.13749 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2024. Verfasst von Fang Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Changhai Hospital Affiliated to Navy Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery, Neutrophils. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Changhai Hospital, Navy Medical University, Shanghai Health Commission Leading Talent Program, Changhai Hospital Guhai Program.
Abstract (Originalsprache)
Background and Objective The neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) were significant and succinct indicators of systemic inflammation. We assessed the influence of stereotactic body radiotherapy (SBRT) on NLR and PLR in patients with locally advanced non‐small cell lung cancer (LA‐NSCLC).
Methods
We reviewed the medical data of patients with LA‐NSCLC who underwent SBRT between 1 January 2013 and 31 December 2018. NLR and PLR values recorded at pre‐ and post‐SBRT were examined. We assessed the correlation between pre/post‐SBRT NLR and PLR and survival outcomes. The decision tree evaluation was conducted using Chi‐square automatic detection.
Results
In total, 213 patients were included in the study with a median follow‐up duration of 40.00 (ranging from 5.28 to 100.70) months. Upon dichotomization by a median, we identified that post‐SBRT NLR > 5.5 and post‐SBRT PLR > 382.0 were negatively associated with shorter overall survival (OS). In the multivariate assessment, post‐SBRT PLR > 382.0 was the only factor. Based on post‐SBRT PLR, tumor locations, and tumor stage, we categorized patients into low, medium, or high‐risk groups.
Conclusions
Post‐SBRT PLR > 382.0 correlated with survival in patients undergoing SBRT. The decision tree model might play a role in future risk stratification to guide the clinical practice of individualized SBRT for LA‐NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Changhai Hospital Affiliated to Navy Medical University, Shanghai, China.
- Department of Hepatic Surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
ORCID-Profile: Zhen Jia, Xiaofei Zhu
Förderung
- Changhai Hospital, Navy Medical University
- Shanghai Health Commission Leading Talent Program
- Changhai Hospital Guhai Program
Zitieren
APA
Fang, F., Jia, Z., Xie, H., Cao, Y., Zhu, X., Yang, X. Y., Guo, X., & Zhang, H. (2024). Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non‐small cell lung cancer undergoing stereotactic body radiotherapy. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13749
Vancouver
Fang F, Jia Z, Xie H, Cao Y, Zhu X, Yang XY, et al. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non‐small cell lung cancer undergoing stereotactic body radiotherapy. The Clinical Respiratory Journal. 2024. doi:10.1111/crj.13749
BibTeX
@article{Fang2024,
author = {Fang, Fang and Jia, Zhen and Xie, Hongliang and Cao, Yangsen and Zhu, Xiaofei and Yang, Xiao Yu and Guo, Xueling and Zhang, Huojun},
title = {Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non‐small cell lung cancer undergoing stereotactic body radiotherapy},
journal = {The Clinical Respiratory Journal},
year = {2024},
doi = {10.1111/crj.13749}
}
EUVIMED